Its suppression enhances PD-L1 degradation via YTHDF2-mediated mRNA decay, potentially sensitizing ccRCC to anti-PD-1/PD-L1 therapies (Zhan et al., 2023). Here, CD274 is linked to nonpapillary renal cell carcinoma.